Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imipenem + relebactam + aztreonam
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Imipenem + relebactam + aztreonam** is an investigational combination antibacterial regimen consisting of the carbapenem antibiotic imipenem, the diazabicyclooctane beta-lactamase inhibitor relebactam, and the monobactam antibiotic aztreonam. This combination is being evaluated for the treatment of serious, multidrug-resistant (MDR) Gram-negative bacterial infections, particularly those caused by pathogens co-producing metallo-beta-lactamases (MBLs, such as NDM, VIM, or IMP) and serine beta-lactamases (such as KPC or AmpC). Aztreonam is uniquely stable against hydrolysis by MBLs but is vulnerable to serine beta-lactamases. Relebactam protects aztreonam from degradation by inhibiting class A and class C serine beta-lactamases, while imipenem provides additional broad-spectrum bactericidal activity against susceptible co-pathogens. The combination is typically administered as a co-administration of the approved fixed-dose combination imipenem/cilastatin/relebactam (Recarbrio) alongside aztreonam.
- Other names
- I/R + ATMI/R plus ATMICR + ATMICR plus ATMRecarbrio + aztreonamRecarbrio plus aztreonamimipenem + relebactam + aztreonamimipenem-relebactam + aztreonamimipenem-relebactam plus aztreonamimipenem/cilastatin/relebactam + aztreonamimipenem/cilastatin/relebactam plus aztreonamimipenem/relebactam + aztreonamimipenem/relebactam plus aztreonam
02
Targets
AmpC (AmpC beta-lactamase)Class A BL (Class A beta-lactamase)KPC (Klebsiella pneumoniae carbapenemase)PBP1A (Penicillin-binding protein 1A)PBP2 (Penicillin-binding protein 2)PBP3 (Peptidoglycan D,D-transpeptidase FtsI)PBP1b (Penicillin-binding protein 1B)
Beyond the preview
Go deeper on imipenem + relebactam + aztreonam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imipenem + relebactam + aztreonam.